Treatment outcomes in Chronic Phase Chronic Myeloid Leukaemia (CP-CML) have
dramatically improved with the introduction of highly active tyrosine kinase inhibitors (TKIs) …

Multiple BCR-ABL tyrosine kinase inhibitors (TKIs) are available for the treatment of chronic
myeloid leukemia in chronic phase (CML-CP), and several baseline and on-treatment …

Response to frontline BCR-ABL1-targeted tyrosine kinase inhibitor (TKI) therapy is
associated with an improved prognosis for patients with chronic myeloid leukemia (CML) …

With treatment-free remission (TFR) rapidly becoming the ultimate goal of therapy in chronic
myeloid leukemia (CML), there is a need to develop strategies to maximize sustained TFR …

Introduction: Several recent studies have shown the speed and depth of response to
tyrosine kinase inhibitor (TKI) treatment to be an important indicator of patient outcomes in …

BCR-ABL1 tyrosine kinase inhibitors (TKIs) improve long-term survival of patients with
chronic-phase (CP) chronic myeloid leukemia (CML). Recently, the treatment goal for …

Background: Continuous treatment with tyrosine kinase inhibitors (TKI) leads to long‐term
remission in most patients with chronic myeloid leukaemia (CML), but is costly and …

Abstract Purpose of Review Although tyrosine kinase inhibitors (TKIs) spectacularly improve
the disease burden and the overall survival of chronic myeloid leukemia patients, early …

Abstract Background. Over 50% of CP-CML patients will achieve a deep molecular
response (DMR) at some point during treatment with Tyrosine Kinase Inhibitors (TKI), where …

Background Several clinical trials in chronic phase (CP) chronic myeloid leukemia (CML)
showed that early response to tyrosine kinase inhibitor (TKI) treatment results in an …